NASDAQ:CAPS Capstone Therapeutics (CAPS) Stock Price, News & Analysis $1.31 -0.09 (-6.43%) As of 10/3/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Capstone Therapeutics Stock (NASDAQ:CAPS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Capstone Therapeutics alerts:Sign Up Key Stats Today's Range$1.29▼$1.3950-Day Range$1.01▼$1.7852-Week Range$0.96▼$16.18Volume289,749 shsAverage Volume1.39 million shsMarket Capitalization$8.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona. Read More Receive CAPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capstone Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPS Stock News HeadlinesMichael ParkerJune 18, 2025 | latimes.comCapstone Holding Corp., Secures $1 Million Pangaea Stone Order in Expanding TerritoryJune 17, 2025 | finanznachrichten.deNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.October 4 at 2:00 AM | Paradigm Press (Ad)Pinecrest, Florida Resident David Buitrago Completes Intensive Capstone Research ProjectJune 16, 2025 | msn.comA capstone projectJune 14, 2025 | yahoo.comCSM Honors 32 Leaders in 2025 Academy CeremonyJune 14, 2025 | msn.comCapstone Holding Corp. (J7W.F)June 12, 2025 | finance.yahoo.comStudents At NHTI, Concord’s Community College, Solve DNA Extraction ConundrumJune 10, 2025 | msn.comSee More Headlines CAPS Stock Analysis - Frequently Asked Questions How have CAPS shares performed this year? Capstone Therapeutics' stock was trading at $2.40 at the start of the year. Since then, CAPS shares have decreased by 45.4% and is now trading at $1.31. How were Capstone Therapeutics' earnings last quarter? Capstone Therapeutics Corp. (NASDAQ:CAPS) announced its quarterly earnings results on Friday, August, 15th. The company reported ($0.13) earnings per share for the quarter. The firm had revenue of $12.85 million for the quarter. When did Capstone Therapeutics IPO? Capstone Therapeutics (CAPS) raised $5 million in an initial public offering on Thursday, March 6th 2025. The company issued 1,250,000 shares at a price of $4.00 per share. When did Capstone Therapeutics' lock-up period expire? Capstone Therapeutics's lock-up period expired on Tuesday, September 2nd. Capstone Therapeutics had issued 1,250,000 shares in its IPO on March 6th. The total size of the offering was $5,000,000 based on an initial share price of $4.00. Since the expiration of Capstone Therapeutics' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted. How do I buy shares of Capstone Therapeutics? Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/15/2025Today10/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CAPS CIK887151 WebN/A Phone(708) 371-0660Fax602-286-5300Employees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.22 Current Ratio0.97 Quick Ratio0.41 Sales & Book Value Annual Sales$43.38 million Price / Sales0.19 Cash FlowN/A Price / Cash FlowN/A Book Value($19.40) per share Price / Book-0.07Miscellaneous Outstanding Shares6,306,000Free Float3,607,000Market Cap$8.26 million OptionableN/A Beta-0.81 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CAPS) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredThe next biggest bull run in over 50 yearsGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.